Methods for treating Parkinson's disease

JP2023552700A5Inactive Publication Date: 2024-11-26NEURODERM LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023529002
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-05-28
Filing Date
2021-11-16
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for Parkinson's disease using levodopa suffer from short plasma half-life, leading to pulsed dopaminergic stimulation and motor fluctuations, which can cause significant disability.

Method used

A treatment regimen involving the parenteral administration of levodopa and a dopa decarboxylase inhibitor, such as carbidopa, combined with oral administration of carbidopa, to provide continuous and physiological delivery of dopamine to the brain, using a subcutaneous infusion and oral immediate-release tablets or capsules.

Benefits of technology

This approach achieves a more stable plasma levodopa concentration, reducing motor fluctuations and improving treatment efficacy for Parkinson's disease by maintaining consistent dopamine levels.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Disclosed are methods for treating a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), e.g., carbidopa, benserazide, or any combination thereof, concomitant with oral administration of levodopa, a DDCI, e.g., carbidopa, benserazide, or any combination thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Related Applications

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 114,688, filed November 17, 2020, and U.S. Patent Application No. 17 / 334,554, filed May 28, 2021, the disclosures of each of which are incorporated by reference in their entirety into this specification. [Technical Field]

[0002]

[0002] The present invention provides a method for treating neurological or movement disorders, such as Parkinson's disease, by parenteral administration of levodopa or a prodrug thereof, and a dopa decarboxylase inhibitor (DDCI) or a prodrug thereof, such as carbidopa, benserazide, or any combination thereof, accompanied by oral administration of levodopa or a prodrug thereof, a dopa decarboxylase inhibitor (DDCI) or a prodrug thereof, such as carbidopa, benserazide, or any combination thereof. [Background technology]

[0003]

[0003] Parkinson's disease is a degenerative condition characterized by reduced levels of the neurotransmitter dopamine in the brain. Levodopa (L-dopa or L-3,4-dihydroxyphenylalanine), a readily metabolic precursor of dopamine that, unlike dopamine, can cross the blood-brain barrier, is most commonly used to restore dopamine levels in the brain. Over the past 40 years, levodopa has consistently been the most effective therapy for the treatment of Parkinson's disease.

[0004]

[0004] However, levodopa has a short plasma half-life, and even under the best current standard of care, dopaminergic stimulation is pulsatile. Therefore, long-term treatment is associated with motor fluctuations and movement disorders that can represent a significant source of disability for certain patients. Ultimately, a therapeutic strategy that can deliver levodopa / dopamine to the brain more continuously and physiologically, while providing the benefits of standard levodopa with reduced motor complications, is greatly needed by patients suffering from Parkinson's disease and other neurological or movement disorders. Summary of the Invention

[0005]

[0005] Provided herein are, inter alia, methods and pharmaceutical compositions for the treatment of neurological or movement disorders, comprising parenteral administration of levodopa, a prodrug or salt thereof (e.g., a pharmaceutically acceptable prodrug salt thereof), a composition (e.g., a pharmaceutically acceptable composition, e.g., a liquid pharmaceutical composition) comprising the same and a dopa decarboxylase inhibitor (DDCI), a prodrug or salt thereof (e.g., a pharmaceutically acceptable prodrug or salt thereof), a composition (e.g., a pharmaceutically acceptable composition, e.g., a liquid pharmaceutical composition) comprising the same, accompanied by oral administration of an active agent selected from the group consisting of levodopa, a levodopa salt, a levodopa prodrug, a dopa decarboxylase inhibitor (DDCI), a prodrug or salt thereof (e.g., a pharmaceutically acceptable salt thereof), and a composition (e.g., a pharmaceutically acceptable composition, e.g., a liquid pharmaceutical composition) comprising the same. Also disclosed are kits for administration of the described methods, and treatment regimens for administration of the described methods, specified by the time course and amount of the pharmaceutical composition.

[0006] An embodiment of the present invention is a method for treating Parkinson's disease in a patient in need thereof, comprising: subcutaneously administering to the patient, over a subcutaneous infusion time course of at least about 24 hours, a pharmaceutically acceptable liquid composition comprising levodopa and carbidopa in amounts delivering about 720 mg of levodopa and about 90 mg of carbidopa to the patient over a time course of at least about 24 hours; orally administering to the patient one or more immediate-release tablets or capsules containing 100 mg of levodopa before or during the subcutaneous infusion time course; The present invention relates to a method comprising:

[0007] According to some embodiments, the pharmaceutically acceptable liquid composition further comprises arginine. According to some embodiments, the pharmaceutically acceptable liquid composition further comprises at least one antioxidant. According to some embodiments, the immediate-release tablet or capsule further comprises carbidopa.

[0008]

[0008] According to some embodiments, with subcutaneous administration and oral administration, the plasma levodopa area under the curve (AUC) from time 0 to the end of the infusion period in a patient is higher compared to the combination of: i) the plasma levodopa AUC from time 0 to the end of the infusion period in a patient to whom the pharmaceutically acceptable liquid composition alone is administered subcutaneously for at least about 24 hours; and ii) the plasma levodopa AUC in a patient to whom oral levodopa alone is administered.

[0009] A further embodiment of the present invention is a method for treating Parkinson's disease in a patient in need thereof, comprising: subcutaneously administering to the patient, over a subcutaneous infusion time course of at least about 24 hours or more, a first pharmaceutically acceptable liquid composition comprising levodopa, carbidopa, arginine, and an antioxidant in an amount to deliver about 720 mg of levodopa and about 90 mg of carbidopa to the patient over at least about 24 hours; orally administering to the patient at least one oral dosage form comprising levodopa before or during the subcutaneous infusion time course; The present invention relates to a method comprising:

[0010]

[0010] According to some embodiments, the oral dosage form contains one of: 50 mg levodopa, 75 mg levodopa, 95 mg levodopa, 100 mg levodopa, 125 mg levodopa, 145 mg levodopa, 150 mg levodopa, 195 mg levodopa, 200 mg levodopa, 245 mg levodopa, or 250 mg levodopa.

[0011] A further embodiment of the present invention is a method for treating Parkinson's disease in a patient currently receiving levodopa and carbidopa in the form of oral immediate-release levodopa and carbidopa alone and in need of further treatment, comprising: subcutaneously administering to the patient a first pharmaceutically acceptable liquid composition comprising levodopa, carbidopa, arginine, and an antioxidant in an amount to deliver about 720 mg of levodopa and about 90 mg of carbidopa to the patient over a 24-hour subcutaneous infusion time course for at least about 24 hours; administering to the patient at least one tablet or capsule containing 100 mg of levodopa and 25 mg of carbidopa daily orally before or during the subcutaneous infusion time course; The present invention relates to a method comprising:

[0012]

[0012] Disclosed herein is a method for treating a neurological or movement disorder in a patient in need of such treatment, comprising: parenterally administering to the patient a first pharmaceutical composition comprising: a) levodopa, a levodopa salt, a levodopa prodrug, or any combination thereof; and b) a dopa decarboxylase inhibitor (DDCI), a DDCI salt, a DDCI prodrug, or any combination thereof; and concomitantly, orally administering to the patient a second pharmaceutical composition comprising an active agent selected from the group consisting of levodopa, a levodopa salt, a levodopa prodrug, a dopa decarboxylase inhibitor (DDCI), a DDCI salt, a DDCI prodrug, and any combination thereof.

[0013]

[0013] In some embodiments, the methods described herein include a DDCI that comprises, consists of, or consists essentially of carbidopa, benserazide, or any combination thereof.

[0014] In some embodiments, the methods described herein include a DDCI in the first pharmaceutical composition that is the same as a DDCI in the second pharmaceutical composition.

[0015] In some embodiments, the methods described herein include a DDCI in a first pharmaceutical composition that is different from the DDCI in a second pharmaceutical composition.

[0015]

[0016] In some embodiments, the methods described herein include levodopa and a DDCI as the second pharmaceutical composition.

[0017] In some embodiments, the methods described herein include the DDCI carbidopa.

[0016]

[0018] In some embodiments, the methods described herein comprise subcutaneous, transdermal, intradermal, intravenous, intramuscular, intratracheal, intranasal, intrathecal, intragastric, or intraduodenal administration of the first pharmaceutical composition.

[0017]

[0019] In some embodiments, the methods described herein include subcutaneous administration of the first pharmaceutical composition.

[0020] In some embodiments, the methods described herein comprise administering the pharmaceutical composition to a patient in need thereof via one or more sites.

[0018]

[0021] In some embodiments, the neurological or movement disorder related to the methods described herein includes Parkinson's disease; secondary parkinsonism, such as drug-induced secondary parkinsonism, neuroleptic-induced parkinsonism, postencephalitic parkinsonism, and vascular parkinsonism; motor fluctuations; neurodegenerative disorders; movement disorders; decreased dopamine levels in the brain; levodopa-induced dyskinesia; rapid eye movement sleep behavior disorder (RBD); dystonia; morning akinesia; tremor symptoms, such as essential tremor and drug-induced Examples of conditions that may be present include: neuroleptic malignant syndrome; Huntington's chorea; Shy-Drager syndrome; brain injury-induced conditions, such as carbon monoxide or manganese poisoning; or any combination thereof; for example, provided herein are methods of treating a patient suffering from Parkinson's disease.

[0019]

[0022] Typically, physicians assess the severity of Parkinson's disease patients according to subjective and objective signs and symptoms, for example, using various scales, and prescribe levodopa dosages accordingly. One well-known and widely used scale for diagnosing and scaling the severity of Parkinson's disease is the Unified Parkinson's Disease Rating Scale (UPDRS). Modified versions of the UPDRS may also be used to classify Parkinson's disease patients. Another known method for measuring the severity of Parkinson's disease is according to the Hohn-Yarr (H&Y) stage, which includes a five-stage scale, with stages 1-2 considered to be mild or early Parkinson's disease patients, stage 3 considered to be moderate or intermediate Parkinson's disease patients, and stages 4-5 considered to be advanced Parkinson's disease patients. The daily levodopa dosage may be appropriately determined and varied by physicians according to a particular patient's condition, the patient's response to treatment, etc., for example, according to clinical findings and a "trial and error" method. Furthermore, patients may be administered different daily doses on different days depending on signs and symptoms, and the range of administered daily doses may be determined by a physician, thereby allowing patient flexibility in treatment. Physicians generally refer to signs as objective measures and symptoms as subjective measures.

[0020]

[0023] According to some embodiments, provided herein are methods of treating patients with advanced Parkinson's disease. According to some embodiments, provided herein are methods of treating patients with advanced Parkinson's disease and / or patients with moderate Parkinson's disease. According to some embodiments, provided herein are methods of treating patients with motor fluctuations. According to some embodiments, provided herein are methods of treating patients with Parkinson's disease with motor fluctuations.

[0021]

[0024] According to some embodiments, provided herein are methods of treating a patient with Parkinson's disease in need of a dose of more than about 300 mg levodopa / day, more than about 400 mg levodopa / day, more than about 500 mg levodopa / day, more than about 600 mg levodopa / day, more than about 700 mg levodopa / day, more than about 800 mg levodopa / day, more than about 900 mg levodopa / day, or more than about 1000 mg levodopa / day.

[0022]

[0025] According to some embodiments, provided herein is a method for treating a Parkinson's disease patient who requires a high dose of levodopa at a specific time, e.g., in the morning, e.g., at the end (about the last time) of a low activity / evening period, e.g., at the beginning (about the first time) of a high activity / daytime period. For example, according to some embodiments, there may be a specific rate for the high activity / daytime period and a different rate for the low activity / evening period, and the high dose of levodopa may be administered at the end of the low activity / evening period, at the end of the low activity / evening period, at the beginning of the high activity / daytime period, etc. Such a high dose may be provided by oral administration of a second pharmaceutical composition, e.g., at the time points mentioned above, provided concomitantly with a substantially continuous first pharmaceutical composition.

[0023]

[0026] According to some embodiments, provided herein are methods of treating a patient who has had Parkinson's disease for more than about 4 years, more than about 5 years, more than about 6 years, more than about 7 years, more than about 8 years, more than about 9 years, or more than about 10 years.

[0024]

[0027] According to some embodiments, provided herein are methods of treating a Parkinson's disease patient suffering from at least 1 hour, at least 1.5 hours, at least 2 hours, at least 2.5 hours, or at least 3 hours of "off time" per day, where "off time" refers to the recurrence of Parkinson's symptoms between medication administrations.

[0025]

[0028] In some embodiments, the methods described herein comprise substantially continuous administration of the first pharmaceutical composition.

[0029] In some embodiments, the methods described herein comprise administering the second pharmaceutical composition 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times per day.

[0026]

[0030] In some embodiments, the methods described herein include administering a second pharmaceutical composition when symptoms from said neurological or movement disorder require said administration.

[0031] In some embodiments, the methods described herein include administering a second pharmaceutical composition at predefined times, at predefined intervals, or both.

[0027]

[0032] In some embodiments, the methods described herein include multiple administrations of the second pharmaceutical composition, wherein the administered dose is the same in all administrations.

[0033] In some embodiments, the methods described herein include multiple administrations of the second pharmaceutical composition, wherein the administered dose is different in at least two of the administrations.

[0028]

[0034] In some embodiments, the methods described herein comprise administering the second pharmaceutical composition at a dose of about 25 mg to about 400 mg of levodopa, or a salt or prodrug thereof, in each administration.

[0029]

[0035] In some embodiments, the methods described herein include levodopa, carbidopa, and arginine, or any salts or prodrugs thereof, as a first pharmaceutical composition.

[0030]

[0036] In some embodiments, the methods described herein include as a first pharmaceutical composition levodopa, carbidopa, arginine, or any salt or prodrug thereof, and at least one antioxidant.

[0031]

[0037] In some embodiments, the methods described herein include as a first pharmaceutical composition levodopa, carbidopa, arginine, or any salt or prodrug thereof, and at least two antioxidants.

[0032]

[0038] In some embodiments, the methods described herein include, as a first pharmaceutical composition, a composition comprising levodopa, carbidopa, or any salt or prodrug thereof, and a base selected from the group consisting of arginine, NaOH, tris(hydroxymethyl)aminomethane (TRIS), and any combination thereof.

[0033]

[0039] In some embodiments, the methods described herein include, as the first pharmaceutical composition, a composition having a pH in the range of about 6 to about 10, in the range of about 8 to about 10, in the range of about 9 to about 10, in the range of about 9.1 to about 9.8, or about 9.5.

[0034]

[0040] In some embodiments, the methods described herein include, as a first pharmaceutical composition, a composition comprising about 1% to about 40% w / v, about 1% to about 20% w / v, about 1% to about 10% w / v, about 2% to about 8% w / v, about 4% to about 8% w / v, about 5% to about 7% w / v, or about 6% w / v of levodopa, a levodopa prodrug, a levodopa salt, or any combination thereof.

[0035]

[0041] In some embodiments, the methods described herein include, as a first pharmaceutical composition, a composition comprising about 0.5% w / v to about 10% w / v, about 0.5% w / v to about 6% w / v, about 0.5% w / v to about 4% w / v, about 0.5% w / v to about 2% w / v, about 0.5% w / v to about 1% w / v, about 0.75% w / v of carbidopa, a carbidopa salt, a carbidopa prodrug, or any combination thereof.

[0036]

[0042] In some embodiments, the methods described herein include an antioxidant selected from the group consisting of ascorbic acid or a salt thereof, cysteine, e.g., N-acetylcysteine, bisulfite or a salt thereof, glutathione, a tyrosinase inhibitor, a divalent cation, butylated hydroxytoluene (BHT), beta hydroxy acid (BHA) tocopherol, gentisic acid, tocopherol, tocopherol derivatives, thioglycerol, and any combination thereof.

[0037]

[0043] In some embodiments, the methods described herein include a composition comprising as a first pharmaceutical composition about 0.05% w / v to about 2.0% w / v, about 0.5% w / v to about 1.5% w / v, 0.75% w / v, about 0.9% w / v, about 1.0% w / v, about 1.1% w / v, or about 1.25% w / v of an antioxidant or combination of antioxidants.

[0038]

[0044] In some embodiments, the methods described herein include a composition comprising about 5 w / v% to about 30 w / v%, about 10 w / v% to 20 w / v%, about 12.5 w / v% to 17.5 w / v%, about 15 w / v%, or about 15.2 w / v% of a base as the first pharmaceutical composition.

[0039]

[0045] In some embodiments, the methods described herein involve administration of the first pharmaceutical composition via one or two sites.

[0046] In some embodiments, the methods described herein include administering the first pharmaceutical composition in a volume of about 1 ml to about 30 ml per site daily, about 2 ml to about 20 ml per site daily, about 3 ml to about 10 ml per site daily, about 5 ml to about 7 ml per site daily, or about 6 ml per site daily.

[0040]

[0047] Also disclosed herein are a first pharmaceutical composition comprising levodopa, a levodopa salt, a levodopa prodrug, or any combination thereof, and a dopa decarboxylase inhibitor (DDCI), a DDCI salt, a DDCI prodrug, or any combination thereof, and a second pharmaceutical composition comprising levodopa, a levodopa salt, a levodopa prodrug, a dopa decarboxylase inhibitor (DDCI), a DDCI salt, a DDCI prodrug, or any combination thereof, for use as a combination in the treatment of a neurological or movement disorder, wherein the first pharmaceutical composition is formulated as a parenteral composition and the second pharmaceutical composition is formulated as an oral composition.

[0041]

[0048] Also disclosed herein is a kit comprising a first pharmaceutical composition in parenteral form comprising levodopa, a levodopa salt, a levodopa prodrug, or any combination thereof; and a dopa decarboxylase inhibitor (DDCI), a DDCI salt, a DDCI prodrug, or any combination thereof; a second pharmaceutical composition in oral form comprising levodopa, a levodopa salt, a levodopa prodrug; a dopa decarboxylase inhibitor (DDCI), a DDCI salt, a DDCI prodrug; or any combination thereof; and instructions for concomitant administration of the first and second pharmaceutical compositions for the treatment of a neurological or movement disorder.

[0042]

[0049] Disclosed herein, in another embodiment, is a method for treating a neurological or movement disorder in a patient in need thereof, comprising: subcutaneously administering to the patient a first pharmaceutically acceptable liquid composition comprising levodopa and carbidopa in an amount to deliver about 100 to 200 mg of levodopa and about 12 to about 50 mg of carbidopa to the patient over a subcutaneous infusion time course of about 7 to about 10 hours or more (e.g., about an 8-hour time course); and orally administering to the patient an immediate-release tablet or capsule comprising levodopa and carbidopa before or during the subcutaneous infusion time course. Contemplated immediate-release tablets may contain, for example, 50 mg, 75 mg, 100 mg, 125 mg, or 150 mg of levodopa and / or 2.5 mg, 18.57 mg, 25 mg, 31.25 mg, 37.5 mg, or 50 mg of carbidopa. In some embodiments, the methods described herein involve initial and / or simultaneous oral administration of an immediate-release tablet or capsule at the start of an infusion time course, e.g., oral administration of an immediate-release tablet or capsule may occur substantially simultaneously when the infusion administration begins and / or about 1, 2, 3, 4, or 5 hours after the start of the infusion time course (e.g., about 0 hours or about 4 hours after the start of the infusion time course), and / or about 1, 2, 3, 4, or 5 hours before the start of the infusion time course (e.g., about 0 hours or about 4 hours before the start of the infusion time course).

[0043]

[0050] In some embodiments, the methods described herein include an immediate release tablet or capsule containing 100 mg of levodopa and 25 mg of carbidopa.

[0051] The methods described herein may include subcutaneous administration of a first pharmaceutically acceptable liquid composition comprising levodopa and carbidopa in an amount that delivers about 140 to 170 mg of levodopa and about 16 to about 24 mg of carbidopa to a patient. A contemplated first pharmaceutically acceptable liquid composition may include a liquid composition comprising about 6% by weight levodopa, about 0.75% by weight carbidopa, and about 10% to about 20% by weight arginine.

[0044]

[0052] For example, the methods described herein may include concomitant subcutaneous administration of a first composition and oral administration of a tablet or capsule, wherein the patient's area under the curve (AUC) of levodopa from time 0 to the end of the infusion period is higher compared to the combination of the patient's levodopa AUC from time 0 to the end of the infusion period when the first composition alone is administered subcutaneously and the patient's levodopa AUC when the tablet or capsule is administered alone, and the amount of levodopa concomitantly administered subcutaneously and orally is about the same as the combined amount of levodopa administered subcutaneously alone and orally alone.

[0045]

[0053] Also disclosed herein is a method of treating a neurological or movement disorder in a patient in need thereof, comprising: subcutaneously administering to the patient a first pharmaceutically acceptable liquid composition comprising about 6% by weight levodopa and about 0.75% by weight carbidopa over a subcutaneous infusion time course of about 7 to about 10 hours or more; and orally administering to the patient an immediate-release tablet or capsule comprising 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 200 mg, or 250 mg of levodopa before or during the subcutaneous infusion time course, wherein the immediate-release tablet or capsule optionally further comprises carbidopa.

[0046]

[0054] Also disclosed herein is a method of treating a neurological or movement disorder in a patient in need thereof, comprising: subcutaneously administering to the patient, over a subcutaneous infusion time course of about 24 hours or more, a first pharmaceutically acceptable liquid composition comprising levodopa and carbidopa in amounts to deliver about 720 mg of levodopa and about 90 mg of carbidopa to the patient over about 24 hours; and orally administering to the patient, before or during the subcutaneous infusion time course, a tablet or capsule, e.g., an immediate-release or modified-release, e.g., extended-release tablet or capsule, comprising levodopa and carbidopa.

[0047]

[0055] In some embodiments, the methods disclosed herein include administering subcutaneous infusions over about 18 hours at a high activity rate and over about 6 hours at a low activity rate, wherein about 691.2 mg of levodopa and about 86.4 mg of carbidopa are administered over 18 hours at the high activity rate and about 28.8 mg of levodopa and 3.6 mg of carbidopa are administered over 6 hours at the low activity rate.

[0048]

[0056] According to some embodiments, the tablet or capsule is orally administered substantially simultaneously with the start of the infusion time course. The tablet or capsule may be administered at predefined intervals during the infusion or as desired or required based on feedback, e.g., to the patient, caregiver, physician, sensor, etc. The intervals at which the tablets or capsules are administered may be substantially the same as or different from each other. According to some embodiments, the tablet or capsule is orally administered about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 hours after the start of the infusion time course, and any number of tablets or capsules may be administered as detailed herein. According to some embodiments, the tablet or capsule contains 100 mg of levodopa and 25 mg of carbidopa.

[0049]

[0057] According to some embodiments, the first pharmaceutically acceptable liquid composition administered over 24 hours in accordance with the methods of the present invention comprises about 6% by weight levodopa, about 0.75% by weight carbidopa, and about 10% to about 20% by weight arginine.

[0050]

[0058] According to some embodiments, whether the first pharmaceutically acceptable liquid composition is administered for 24 hours or more according to the methods of the present invention in conjunction with oral administration of a tablet or capsule as detailed herein, the patient's area under the curve (AUC) of levodopa from time 0 to the end of the infusion period is higher than the patient's levodopa AUC from time 0 to the end of the infusion period when the patient is subcutaneously administered the first composition alone compared to the patient's levodopa AUC from time 0 to the end of the infusion period when the patient is administered the tablet or capsule alone and when the amount of levodopa concomitantly administered subcutaneously and orally is approximately the same as the combined amount of levodopa administered subcutaneously and orally alone. DETAILED DESCRIPTION OF THE INVENTION

[0051] Detailed Description of the Invention

[0059] The features and other details of the present disclosure will now be described in more detail.Specific terms used in the specification, examples, and appended claims are collected here.These definitions should be read in light of the remainder of the disclosure and understood by those skilled in the art.Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art.

[0052]

[0060] The terms "treat," "treatment," "treating," and the like are used herein generally to refer to obtaining a desired pharmacological and / or physiological effect. The effect may be therapeutic in that it partially or completely cures the disease and / or the adverse effects caused by the disease. As used herein, the term "treatment" encompasses any treatment of disease in a mammal, particularly a human, including: (a) inhibiting the disease, i.e., preventing the disease from increasing in severity or extent; (b) alleviating the disease, i.e., causing partial or complete remission of the disease; or (c) preventing the recurrence of the disease, i.e., preventing the disease from returning to an active state, after previously successful treatment of the symptoms of the disease or treatment of the disease.

[0053]

[0061] "Prevention" includes delaying the onset of clinical symptoms, complications, or biochemical signs of a condition, disorder, disease, or condition that manifests in a subject who may be afflicted with or prone to the condition, disorder, disease, or condition, but who has not yet experienced or exhibited clinical or subclinical symptoms of the condition, disorder, disease, or condition. "Prevention" includes prophylactically treating a condition, disorder, disease, or condition in or that manifests in a subject, including prophylactically treating clinical symptoms, complications, or biochemical signs of a condition, disorder, disease, or condition in or that manifests in a subject.

[0054]

[0062] The terms "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient," used interchangeably herein, refer to any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.

[0055]

[0063] As used herein, the terms "pharmaceutical composition" and "pharmaceutical formulation" refer to a composition or formulation comprising at least one biologically active compound, e.g., levodopa or carbidopa, or a pharmaceutically acceptable salt or prodrug thereof, formulated together with one or more pharmaceutically acceptable excipients.

[0056]

[0064] As used herein, the term "pharmaceutically acceptable salt" refers to salts of acidic or basic groups that can be formed by the conjugates used in the compositions disclosed herein.

[0057]

[0065] "Individual," "patient," or "subject" are used interchangeably and include any animal, including mammals, mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses, or non-human primates, and humans. In some embodiments, the mammal treated by the methods of the invention is a human suffering from a neurodegenerative condition, e.g., Parkinson's disease.

[0058]

[0066] As used herein, the term "about" is considered to cover a range of ±10% of the stated value unless specifically stated otherwise or understood otherwise by one of ordinary skill in the art. Furthermore, any value provided can also be considered to cover a range of ±10% of the value in question without the use of the term "about." This includes values ​​in the Examples section, which may vary according to the instruments and equipment used, the purity of the compounds, etc.

[0059]

[0067] As used herein, the term "liquid" refers to any type of fluid, including gels, aqueous and non-aqueous compositions, unless specifically stated otherwise or understood otherwise by one of ordinary skill in the art.

[0060]

[0068] The term "concomitant" as used herein, unless specifically stated otherwise or understood by those skilled in the art, refers to any type of combined administration of two or more active ingredients in the same composition, as well as simultaneous administration of the active ingredients in separate compositions, and administration of two or more active ingredients sequentially, consecutively, or on the same day with a predefined period separating the administration of the active ingredients, etc. The term "concomitant" may also be used herein to refer to any type of combined administration of two separate pharmaceutical compositions, where each composition may be administered at different time intervals, doses, etc., and by different administration routes. For example, as detailed herein, one composition may be administered parenterally, e.g., subcutaneously, substantially continuously, while a second composition is administered discontinuously, orally, concomitantly with the first composition. Furthermore, the concomitant administration of two or more separate compositions may be dependent on or independent of each other.

[0061]

[0069] As used herein, the terms "continuously" and "substantially continuously," unless specifically stated otherwise or understood by one of ordinary skill in the art, refer to a period during which the composition is administered over a period of about 24 hours, about 12 hours, about 5 hours, about 3 hours, about 1 hour, about 30 minutes, about 15 minutes, about 5 minutes, or less than about 1 minute of interruption. The period during which the composition is administered may be at least about 6 hours, about 8 hours, about 12 hours, about 15 hours, about 18 hours, about 21 hours, about 24 hours, 3 days, 7 days, 2 weeks, 1 month, 3 months, 6 months, 1 year, 2 years, 3 years, 5 years, 10 years, etc.

[0062]

[0070] As used herein, the term "physiologically acceptable pH value" refers to a pH value within the range of about 4.5 to about 10, unless specifically stated otherwise or understood otherwise by one of ordinary skill in the art. Furthermore, when pH values ​​are provided in the examples, for example, the values ​​may be within a range of about ±0.1 and / or ±10% of the stated value, and it is noted that if the measured pH is 8.1, the same formulation may be prepared to provide a pH of about 8.0 or 8.2. Such differences may be due to temperature variations, different measuring devices, etc.

[0063]

[0071] Neuropathies are disorders of the body's nervous system, and the term "movement disorder" as used herein refers to a condition of the nervous system that causes abnormal voluntary or involuntary movements, or slow, sluggish movements. According to some embodiments, the neurological or movement disorder is Parkinson's disease; secondary parkinsonism, such as drug-induced secondary parkinsonism, neuroleptic-induced parkinsonism, postencephalitic parkinsonism, and vascular parkinsonism; motor fluctuations; neurodegenerative disorders; movement disorders; reduced dopamine levels in the brain; levodopa-induced dyskinesia; rapid eye movement sleep behavior disorder (RBD); dystonia; morning akinesia; tremor symptoms, such as essential tremor and drug-induced tremor; myoclonus; chorea, such as drug-induced chorea; tics, such as drug-induced tics and organic tics; drug-induced movement dyspraxia; drug-induced akathisia; restless legs syndrome (RLS); stiff-man syndrome; benign tremor attacks; neuroleptic malignant syndrome; Huntington's chorea; Shy-Drager syndrome; brain injury-induced conditions, such as carbon monoxide or manganese poisoning; or any combination thereof.

[0064]

[0072] As used herein, the term "dopa decarboxylase inhibitor" refers to agents, such as carbidopa and benserazide, that can inhibit the peripheral metabolism of levodopa to dopamine by aromatic L-amino acid decarboxylase.

[0065]

[0073] As used herein, the terms "morning dose" and "morning oral dose," unless specifically stated otherwise or understood by one of ordinary skill in the art, are interchangeable and refer to an oral dosage form containing levodopa, which is administered particularly in the morning, e.g., within 1 minute, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, of the patient's waking hours. According to some embodiments, the morning dose refers to an oral dosage form containing levodopa, which is administered within 1 minute, 5 minutes, 10 minutes, 15 minutes, 20 minutes, or 30 minutes of the patient's waking hours.

[0066]

[0074] According to some embodiments, the morning oral dose comprises one of: 25 mg levodopa, 50 mg levodopa, 75 mg levodopa, 95 mg levodopa, 100 mg levodopa, 125 mg levodopa, 145 mg levodopa, 150 mg levodopa, 195 mg levodopa, 200 mg levodopa, 245 mg levodopa, or 250 mg levodopa.

[0067]

[0075] An embodiment of the present invention relates to a method of treating a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, the method comprising: levodopa, a levodopa salt, a levodopa prodrug, or any combination thereof; and dopa decarboxylase inhibitors (DDCI), DDCI salts, DDCI prodrugs, or any combination thereof parenterally administering a first pharmaceutical composition comprising: Accompanying this, Levodopa, levodopa salts, levodopa prodrugs; dopa decarboxylase inhibitors (DDCI), DDCI salts, DDCI prodrugs; or any combination thereof orally administering a second pharmaceutical composition comprising Includes.

[0068]

[0076] According to some embodiments, the concomitant administration of the first and second pharmaceutical compositions achieves a synergistic effect such that the concomitant administration results in higher levodopa blood levels than the expected additive effect of providing the first and second pharmaceutical compositions without the concomitant administration. According to some embodiments, the synergistic effect between the first and second pharmaceutical compositions achieves an increase in levodopa blood levels of about 5% to about 50% compared to the expected additive value. According to some embodiments, the synergistic effect between the first and second pharmaceutical compositions achieves an increase in levodopa blood levels of about 10% to 40%, about 15% to 35%, about 20% to 40%, about 25% to 35%, or about 30% compared to the expected additive value.

[0069]

[0077] According to some embodiments, the first pharmaceutical composition comprises levodopa and carbidopa. According to some embodiments, the second pharmaceutical composition comprises levodopa and carbidopa. According to some embodiments, the second pharmaceutical composition comprises only levodopa.

[0070]

[0078] According to some embodiments, the first pharmaceutical composition and / or the second pharmaceutical composition comprises (1) levodopa, a levodopa salt, and / or a levodopa prodrug, and / or (2) carbidopa, a carbidopa salt, and / or a carbidopa prodrug. According to some embodiments, the levodopa prodrug is any of the prodrugs disclosed in PCT / IL2020 / 050960 or US63 / 159,236, which applications are incorporated herein by reference in their entireties. According to some embodiments, the carbidopa prodrug is any of the prodrugs disclosed in JP2021-037959.

[0071]

[0079] According to some embodiments, the DDCI is carbidopa, a carbidopa prodrug, a carbidopa salt, benserazide, a benserazide prodrug, a benserazide salt, or any combination thereof. According to some embodiments, the DDCI is carbidopa. The DDCI in the first pharmaceutical composition may be the same as or different from the DDCI in the second pharmaceutical composition. Furthermore, the levodopa component in each of the first and second pharmaceutical compositions may be the same or different. That is, according to some embodiments, both the first pharmaceutical composition and the second pharmaceutical composition contain levodopa, while according to other embodiments, the first pharmaceutical composition may contain one type of levodopa component, such as a levodopa prodrug and / or a levodopa salt, while the second pharmaceutical composition contains a different type of levodopa component, such as levodopa. Furthermore, it is noted that the concentration or amount of each component in the first pharmaceutical composition may differ from the concentration or amount of that component in the second pharmaceutical composition.

[0072]

[0080] According to some embodiments, the first pharmaceutical composition can be administered by any parenteral administration route, for example, subcutaneously, transdermally, intradermally, intravenously, intramuscularly, intratracheally, intranasally, intrathecally, intragastrically, or intraduodenum. According to some embodiments, the first pharmaceutical composition is administered subcutaneously. According to some embodiments, the first pharmaceutical composition is liquid. According to some embodiments, the first pharmaceutical composition is aqueous.

[0073]

[0081] According to some embodiments, the first pharmaceutical composition is administered substantially continuously. According to some embodiments, the first pharmaceutical composition is administered subcutaneously via a designated pump device.

[0074]

[0082] The specified pump embodiments are described in, for example, US62 / 529,784, US62 / 576,362, PCT / IB2018 / 054962, US16 / 027,804, US16 / 027,710, US10,463,787, US10,463,572, US10,603,430, US16 / 685,364, US2020 / 0093984, USD29 / 655,583, US The pump may be any of the pump embodiments disclosed in US 29 / 655,587, USD 29 / 655,589, USD 29 / 655,591, USD 29 / 655,592, USD 29 / 655,594, USD 29 / 655,597, USD 29 / 723,714, and US 62 / 851,903, all of which applications are incorporated herein by reference in their entirety.

[0075]

[0083] According to some embodiments, the methods of the present invention include administering a first pharmaceutical composition at one site, two sites, or three or more sites, and the location of the sites can be changed at any suitable, possibly predetermined, interval. According to some embodiments, once administration is performed via a particular site, administration via the same site or nearby sites can occur only after a possibly predefined period of time. According to some embodiments, the location of any one of the sites can be changed after 12, 24, 36, 48, 60, or 72 hours. According to some embodiments, the location of the site can be changed after 4, 5, 6, or 7 days. According to some embodiments, the location of the site can be changed after 2, 3, or 4 weeks. According to some embodiments, the location of the site can be changed as needed or desired, for example, according to subjective data received from the patient and / or according to objective data, for example, received from a sensor positioned at or near the injection site.

[0076]

[0084] According to some embodiments, the dosage volume and / or dosage rate is the same for all or at least two of the sites. According to other embodiments, the dosage rate and / or dosage volume varies from site to site. Each site may or may not be administered independently, and all sites may be administered dependently.

[0077]

[0085] According to some embodiments, the method of the present invention comprises subcutaneously administering a first pharmaceutical composition of the present invention over a period of about 5 to about 24 hours or more, such as about 5 to about 12 hours or more, about 7 to about 10 hours or more, or for example about 8 hours or about 24 hours.

[0078]

[0086] According to some embodiments, the dose of the carbidopa component in the first pharmaceutical composition is about 10 mg to about 25 mg per administration, about 10 mg to about 50 mg per administration, about 10 mg to about 75 mg per administration, about 12 mg to about 25 mg per administration, about 12 mg to about 50 mg per administration, about 12 mg to about 75 mg per administration, about 15 mg to about 25 mg per administration, about 15 mg to about 50 mg per administration, about 15 mg to about 75 mg per administration, about 25 mg to about 50 mg per administration, about 25 mg to about 75 mg per administration, or about 50 mg to about 75 mg per administration. According to some embodiments, the dose of the carbidopa component in the first pharmaceutical composition is about 90 mg, and is administered, for example, over about 5 to about 24 hours. According to some embodiments, the dose of the carbidopa component in the first pharmaceutical composition is about 46 mg to about 90 mg per administration. According to some embodiments, the dose of the carbidopa component in the first pharmaceutical composition is about 90 mg, for example, administered over about 24 hours. According to some embodiments, the dose of the carbidopa component in the first pharmaceutical composition is about 46 mg to about 90 mg, for example, administered over about 24 hours.

[0079]

[0087] According to some embodiments, the dose of the levodopa component in the first pharmaceutical composition is from about 10 mg to about 800 mg per dose, from about 10 mg to about 25 mg per dose, from about 25 mg to about 50 mg per dose, from about 50 mg to about 75 mg per dose, from about 75 mg to about 100 mg per dose, from about 100 mg to about 150 mg per dose, from about 150 mg to about 200 mg per dose, from about 100 mg to about 250 mg per dose, from about 150 mg to about 200 mg per dose, from about 100 mg to about 300 mg per dose, from about 100 mg to about 350 mg per dose, from about 150 mg to about 400 mg per dose, from about 150 mg to about 500 mg per dose, from about 150 mg to about 200 mg per dose, from about 150 mg to about 350 mg per dose, from about 150 mg to about 400 mg per dose, from about 150 mg to about 500 mg per dose, from about 150 mg to about 25 ...250 mg per dose, from about 150 mg to about 350 mg per dose, from about 150 mg to about 400 mg per dose, from about 150 mg to about 250 mg per dose, from about 150 mg to about 350 mg per dose, from about 150 mg to about 400 mg per dose, from about 150 The dose of the levodopa component in the first pharmaceutical composition is about 200 mg to about 250 mg per administration, about 250 mg to about 300 mg per administration, about 300 mg to about 350 mg per administration, about 350 mg to about 400 mg per administration, about 400 mg to about 450 mg per administration, about 450 mg to about 500 mg per administration, about 500 mg to about 800 mg, about 600 mg to about 800 mg, about 700 mg to about 800 mg, or about 720 mg per administration. In certain embodiments, the dose of the levodopa component in the first pharmaceutical composition is about 370 mg to about 720 mg. In certain embodiments, the dose is administered over about 5 to about 24 hours (e.g., about 7 to about 10, or about 8 hours or about 24 hours) or more. According to some embodiments, the dose of the levodopa component in the first pharmaceutical composition is about 720 mg, for example, administered over about 24 hours. According to some embodiments, the dose of the levodopa component in the first pharmaceutical composition is about 370 mg to about 720 mg, for example, administered over about 24 hours. According to some embodiments, the dose of the levodopa component in the first pharmaceutical composition is about 360 mg to about 720 mg, for example, administered over about 24 hours. According to some embodiments, the dose of the levodopa component in the first pharmaceutical composition is at most about 720 mg.

[0080]

[0088] In certain embodiments, the first pharmaceutical composition is administered in an amount that delivers about 100 to about 200 mg of levodopa and about 12 to about 50 mg of carbidopa to the patient. In certain embodiments, the first pharmaceutical composition is administered in an amount that delivers about 140 to about 170 mg of levodopa and about 16 to about 24 mg of carbidopa to the patient. In certain embodiments, the dose is administered over about 5 to about 24 (e.g., about 7 to about 10) hours or more. In certain embodiments, the first pharmaceutical composition is administered in an amount that delivers about 650 mg to about 800 mg, e.g., about 720 mg of levodopa, and about 80 mg to about 100 mg, e.g., about 90 mg of carbidopa to the patient over about 24 hours. According to some embodiments, the dose of the carbidopa component in the first pharmaceutical composition is about 46 mg to about 90 mg, for example, administered over about 24 hours. According to some embodiments, the dose of the carbidopa component in the first pharmaceutical composition is about 45 mg to about 90 mg, for example, administered over about 24 hours. According to some embodiments, the dose of the carbidopa component in the first pharmaceutical composition is at most about 90 mg.

[0081]

[0089] According to some embodiments, the method of the present invention comprises subcutaneously administering about 1 to about 30 ml of the first pharmaceutical composition of the present invention over a 24-hour period, or about 1 ml to about 2 ml, about 2 ml to about 3 ml, about 3 ml to about 4 ml, about 4 ml to about 5 ml, about 5 ml to about 6 ml, about 6 ml to about 7 ml, about 7 ml to about 8 ml, about 8 ml to about 9 ml, about 9 ml to about 10 ml, about 10 ml to about 11 ml, about 11 ml to about 12 ml, about 12 ml to about 13 ml, about 13 ml to about 14 ml, about 14 ml to about 15 ml, or about 15 ml to about 16 ml over a 24-hour period. The method comprises subcutaneously administering about 12 ml of the first pharmaceutical composition of the present invention over a period of about 24 hours.

[0082]

[0090] According to some embodiments, the first pharmaceutical composition is administered in a volume of about 1 ml to about 30 ml per site daily, about 2 ml to about 20 ml per site daily, about 3 ml to about 10 ml per site daily, about 5 ml to about 7 ml per site daily, or about 6 ml per site daily. According to some embodiments, the first pharmaceutical composition is administered in a volume of about 1 ml to about 2.5 ml per site daily, about 2.5 ml to about 5.0 ml per site daily, about 5.0 ml to about 7.5 ml per site daily, about 7.5 ml to about 10 ml per site daily, about 10 ml to about 12.5 ml per site daily, about 12.5 ml to about 15 ml per site daily, about 15 ml to about 17.5 ml per site daily, about 17.5 ml to about 20 ml per site daily, about 20 ml to about 22.5 ml per site daily, about 22.5 ml to about 25 ml per site daily, about 25 ml to about 27.5 ml per site daily, or about 27.5 ml to about 30 ml per site daily. According to some embodiments, the first pharmaceutical composition is administered in a volume of about 6 ml per site daily.

[0083]

[0091] The administration rate may be constant over a 24-hour period or may vary over a 24-hour period. For example, according to some embodiments, there may be a constant rate for the high activity / daytime period and a different rate for the low activity / evening period. The high activity / daytime period may be, for example, about 15, about 16, about 17, about 18, or about 19 hours, while the low activity / evening period may be, for example, about 9, about 8, about 7, about 6, or about 5 hours. According to some embodiments, the high activity / daytime rate is administered for about 18 hours, while the low activity / evening rate is administered for about 6 hours. According to some embodiments, the high activity / daytime rate is administered for about 16 hours, while the low activity / evening rate is administered for about 8 hours. According to some embodiments, the administration rate is determined, at least in part, by input received from the patient, a caregiver, at least one sensor, or the like. According to some embodiments, the administration rate may be increased or decreased as needed, e.g., by a caregiver or the patient, according to a predefined pattern that may be periodically set. According to other embodiments, the administration rate may be changed, e.g., increased or decreased, online, e.g., according to input received from the patient, the caregiver, or at least one sensor indicating that a change in administration rate is needed or beneficial. For example, if the patient desires to rest at a particular point during the day, the rate may be decreased from a daytime rate to an evening rate, e.g., by a command provided by the patient. In addition, the caregiver may give commands to the system, e.g., to account for the patient resting during the day. Furthermore, sensors may alert the system that the patient is falling asleep and decrease the administration rate accordingly. Sensors may also provide sleep pattern data, allowing the system to be notified in advance of the patient waking from sleep and responding, e.g., increasing the administration rate. The administration rate may also be changed due to a monitored patient condition, e.g., an "off episode," which may increase the administration rate.

[0084]

[0092] The administration rate may be about 0.01 mL / site / hour to about 1 mL / site / hour. According to some embodiments, the administration rate is about 0.01 to 0.02 mL / site / hour. According to some embodiments, the administration rate is about 0.02 to 0.03 mL / site / hour. According to some embodiments, the administration rate is about 0.03 to 0.04 mL / site / hour. According to some embodiments, the administration rate is about 0.04 to 0.05 mL / site / hour. According to some embodiments, the administration rate is about 0.05 to 0.06 mL / site / hour. According to some embodiments, the administration rate is about 0.06 to 0.07 mL / site / hour. According to some embodiments, the administration rate is about 0.07 to 0.08 mL / site / hour. According to some embodiments, the administration rate is about 0.08 to 0.09 mL / site / hour. According to some embodiments, the administration rate is about 0.09 to 0.1 mL / site / hour. According to some embodiments, the administration rate is about 0.1 to 0.15 mL / site / hour. According to some embodiments, the administration rate is about 0.15 to 0.2 mL / site / hour. According to some embodiments, the administration rate is about 0.2 to 0.25 mL / site / hour. According to some embodiments, the administration rate is about 0.25 to 0.3 mL / site / hour. According to some embodiments, the administration rate is about 0.3 to 0.35 mL / site / hour. According to some embodiments, the administration rate is about 0.35 to 0.4 mL / site / hour. According to some embodiments, the administration rate is about 0.4 to 0.45 mL / site / hour. According to some embodiments, the administration rate is about 0.45 to 0.5 mL / site / hour. According to some embodiments, the administration rate is about 0.5 to 0.55 mL / site / hour. According to some embodiments, the administration rate is about 0.55 to 0.6 mL / site / hour. According to some embodiments, the administration rate is about 0.6 to 0.65 mL / site / hour. According to some embodiments, the administration rate is about 0.65 to 0.7 mL / site / hour. According to some embodiments, the administration rate is about 0.7 to 0.75 mL / site / hour. According to some embodiments, the administration rate is about 0.75 to 0.8 mL / site / hour. According to some embodiments, the administration rate is about 0.8 to 0.85 mL / site / hour.According to some embodiments, the administration rate is about 0.85 to 0.9 mL / site / hour. According to some embodiments, the administration rate is about 0.9 to 0.95 mL / site / hour. According to some embodiments, the administration rate is about 0.95 to 1.0 mL / site / hour.

[0085]

[0093] According to some embodiments, the administration rate for low activity / evening time is about 0.01 to 0.15 mL / site / hour. According to some embodiments, the administration rate for low activity / evening time is about 0.01 to 0.02 mL / site / hour. According to some embodiments, the administration rate for low activity / evening time is about 0.02 to 0.03 mL / site / hour. According to some embodiments, the administration rate for low activity / evening time is about 0.03 to 0.04 mL / site / hour. According to some embodiments, the administration rate for low activity / evening time is about 0.04 to 0.05 mL / site / hour. According to some embodiments, the administration rate for low activity / evening time is about 0.05 to 0.06 mL / site / hour. According to some embodiments, the administration rate for low activity / evening time is about 0.06 to 0.07 mL / site / hour. According to some embodiments, the administration rate for low activity / evening time is about 0.07 to 0.08 mL / site / hour. According to some embodiments, the administration rate for low activity / evening time is about 0.08 to 0.09 mL / site / hour. According to some embodiments, the administration rate for low activity / evening time is about 0.09 to 0.1 mL / site / hour. According to some embodiments, the administration rate for low activity / evening time is about 0.1 to 0.11 mL / site / hour. According to some embodiments, the administration rate for low activity / evening time is about 0.11 to 0.12 mL / site / hour. According to some embodiments, the administration rate for low activity / evening time is about 0.12 to 0.13 mL / site / hour. According to some embodiments, the administration rate for low activity / evening time is about 0.13 to 0.14 mL / site / hour. According to some embodiments, the administration rate for low activity / evening time is about 0.14-0.15 mL / site / hour. According to some embodiments, the administration rate for low activity / evening time is about 0.04 mL / site / hour. According to some embodiments, the administration rate for low activity / evening time is about 0.08 mL / site / hour.

[0086]

[0094] According to some embodiments, the administration rate during high activity / daytime is about 0.15 to 1.0 mL / site / hour. According to some embodiments, the administration rate during high activity / daytime is about 0.15 to 0.2 mL / site / hour. According to some embodiments, the administration rate during high activity / daytime is about 0.2 to 0.25 mL / site / hour. According to some embodiments, the administration rate during high activity / daytime is about 0.25 to 0.3 mL / site / hour. According to some embodiments, the administration rate during high activity / daytime is about 0.3 to 0.35 mL / site / hour. According to some embodiments, the administration rate during high activity / daytime is about 0.35 to 0.4 mL / site / hour. According to some embodiments, the administration rate during high activity / daytime is about 0.4 to 0.45 mL / site / hour. According to some embodiments, the administration rate for high activity / daytime is about 0.45 to 0.5 mL / site / hour. According to some embodiments, the administration rate for high activity / daytime is about 0.5 to 0.55 mL / site / hour. According to some embodiments, the administration rate for high activity / daytime is about 0.55 to 0.6 mL / site / hour. According to some embodiments, the administration rate for high activity / daytime is about 0.6 to 0.65 mL / site / hour. According to some embodiments, the administration rate for high activity / daytime is about 0.65 to 0.7 mL / site / hour. According to some embodiments, the administration rate for high activity / daytime is about 0.7 to 0.75 mL / site / hour. According to some embodiments, the administration rate for high activity / daytime is about 0.75 to 0.8 mL / site / hour. According to some embodiments, the administration rate during high activity / daytime is about 0.8 to 0.85 mL / site / hour. According to some embodiments, the administration rate during high activity / daytime is about 0.85 to 0.9 mL / site / hour. According to some embodiments, the administration rate during high activity / daytime is about 0.9 to 0.95 mL / site / hour. According to some embodiments, the administration rate during high activity / daytime is about 0.95 to 1.0 mL / site / hour. According to some embodiments, the administration rate during high activity / daytime is about 0.32 mL / site / hour. According to some embodiments, the administration rate during high activity / daytime is about 0.32 mL / hour to about 0.64 mL / hour.

[0087]

[0095] As mentioned above, the low and high rates, while referred to as evening and day rates, respectively, may be used regardless of time of day (rather than patient status, e.g., low activity and high activity). Furthermore, the rates may be changed gradually and set at any suitable value and are not necessarily tied to one particular high rate and one particular low rate.

[0088]

[0096] According to some embodiments, the first composition is administered at a high activity rate over about 12 to about 20 hours (e.g., about 18 hours) and at a low activity rate over about 4 to about 12 hours (e.g., about 6 hours), with about 500 mg to about 800 mg (e.g., about 700 mg or about 691.2 mg) of levodopa and about 60 mg to about 100 mg (e.g., about 80 mg or about 86.4 mg) of levodopa being administered during the high activity period, and about 20 mg to about 40 mg (e.g., about 30 mg or about 28.8 mg) of levodopa and about 2 mg to about 5 mg (e.g., about 3 mg or about 3.6 mg) of carbidopa being administered during the low activity period. According to some embodiments, the high activity rate and / or the low activity rate may be administered continuously for a 24-hour period. According to other embodiments, the high activity rate and / or the low activity rate may be administered in several non-continuous periods during a 24-hour period.

[0089]

[0097] It is further noted that the administration volume and / or administration rate may remain constant throughout treatment or may vary between different days and times, during different days, weeks, or months of treatment, etc. According to some embodiments, the patient is monitored, e.g., independently, by an administrator, or electronically, e.g., by a sensor, perhaps found in a dedicated device, e.g., a watch-like device, a patch-like sensor, an administration pump, etc. According to such embodiments, the administration volume and / or rate is determined according to data received from such monitoring.

[0090]

[0098] Some embodiments relate to a method of administering a bolus subcutaneous injection of a first pharmaceutical composition of the present invention. According to some embodiments, the bolus injection comprises about 0.5 to about 2.0 mL / kg of the first pharmaceutical composition. According to some embodiments, the bolus injection comprises about 0.5 to about 0.75 mL / kg of the first pharmaceutical composition. According to some embodiments, the bolus injection comprises about 0.75 to about 1.0 mL / kg of the first pharmaceutical composition. According to some embodiments, the bolus injection comprises about 1.0 to about 1.25 mL / kg of the first pharmaceutical composition. According to some embodiments, the bolus injection comprises about 1.25 to about 1.5 mL / kg of the first pharmaceutical composition. According to some embodiments, the bolus injection comprises about 1.5 to about 1.75 mL / kg of the first pharmaceutical composition. According to some embodiments, the bolus injection comprises about 1.75 to about 2.0 mL / kg of the first pharmaceutical composition. According to some embodiments, the bolus injection comprises about 0.75 to about 1.25 mL / Kg of the first pharmaceutical composition. According to some embodiments, the bolus injection comprises about 1.0 mL / Kg of the first pharmaceutical composition.

[0091]

[0099] The bolus subcutaneous injection may be administered at any time, for example, before, during, or after any consecutive subcutaneous administrations. The bolus subcutaneous injection may be administered at any time during the day. The bolus subcutaneous injection may be administered once daily, once every 2, 3, 4, 5, or 6 days, once a week, or more. The bolus subcutaneous injection may be administered as needed / desired according to feedback received from the patient, caregiver, physician, sensor, etc., and / or according to a predefined regimen. The bolus subcutaneous injection may be administered over a period of about 5 to about 40 minutes, about 5 to about 10 minutes, about 10 to 15 minutes, about 15 to 20 minutes, about 20 to 25 minutes, about 25 to 30 minutes, about 30 to 35 minutes, or about 35 to 40 minutes.

[0092]

[0100] According to some embodiments, the administered dose may be doubled, tripled, or more by using multiple pumps, multiple injection sites per pump, or the like.

[0101] According to some embodiments, the first pharmaceutical composition is administered for a defined period of time, for example, days, weeks, months, or years. According to some embodiments, the first pharmaceutical composition is administered continuously for the treatment of chronic conditions.

[0093]

[0102] According to some embodiments, the first pharmaceutical composition comprises about 1% to about 40% w / v of levodopa, a levodopa prodrug, a levodopa salt, or any combination thereof. According to some embodiments, the first pharmaceutical composition comprises about 1% to about 5% w / v, about 5% to about 10% w / v, about 10% to about 15% w / v, about 15% to about 20% w / v, about 20% to about 25% w / v, about 25% to about 30% w / v, about 30% to about 35% w / v, about 35% to about 40% w / v, about 2% to about 10% w / v, about 4% to about 8% w / v, about 5% to about 7% w / v, or about 6% w / v of levodopa, levodopa prodrug, levodopa salt, or any combination thereof.

[0094]

[0103] According to some embodiments, the first pharmaceutical composition comprises about 0.5% w / v to about 10% w / v of carbidopa, a carbidopa salt, a carbidopa prodrug, or any combination thereof. According to some embodiments, the first pharmaceutical composition comprises about 0.5% w / v to about 1% w / v, about 1% w / v to about 1.5% w / v, about 1.5% w / v to about 2% w / v, about 2% w / v to about 2.5% w / v, about 2.5% w / v to about 3% w / v, about 3% w / v to about 3.5% w / v, about 3.5% w / v to about 4% w / v, about 4% w / v to about 4.5% w / v, about 4.5% w / v to about 5% w / v, about 5% w / v to about 5.5% w / v, or about 5.5% w / v. about 6 w / v%, about 6 w / v% to about 6.5 w / v%, about 6.5 w / v% to about 7 w / v%, about 7 w / v% to about 7.5 w / v%, about 7.5 w / v% to about 8 w / v%, about 8 w / v% to about 8.5 w / v%, about 8.5 w / v% to about 9 w / v%, about 9 w / v% to about 9.5 w / v%, about 9.5 w / v% to about 10 w / v%, about 0.75 w / v% carbidopa, carbidopa salt, carbidopa prodrug, or any combination thereof.

[0095]

[0104] For example, provided herein is a first pharmaceutical composition suitable for parenteral (e.g., subcutaneous) administration, comprising about 4 to about 10% by weight levodopa, about 0.5 to about 2% by weight carbidopa, and about 10% to about 20% by weight arginine. Another exemplary first pharmaceutical composition provided herein comprises about 6% by weight levodopa, about 0.75% by weight carbidopa, and about 10% to about 20% by weight arginine.

[0096]

[0105] According to some embodiments, the first pharmaceutical composition comprises about 0.05 w / v% to about 2.0 w / v%, about 0.05 w / v% to about 0.1 w / v%, about 0.1 w / v% to about 0.2 w / v%, about 0.2 w / v% to about 0.3 w / v%, about 0.3 w / v% to about 0.4 w / v%, about 0.4 w / v% to about 0.5 w / v%, about 0.5 w / v% to about 0.6 w / v%, about 0.6 w / v% to about 0.7 w / v%, about 0.7 w / v% to about 0.8 w / v%, about 0.8 w / v% to about 0.9 w / v%, about 0.9 w / v% to about 1.0 w / v%, about 1 w / v% to about 1.1 w / v%, or about 1.1 w / v% to about 1.2 w / v%, about 1.2 w / v% to about 1.3 w / v%, about 1.3 w / v% to about 1.4 w / v%, about 1.4 w / v% to about 1.5 w / v%, about 1.5 w / v% to about 1.6 w / v%, about 1.6 w / v% to about 1.7 w / v%, about 1.7 w / v% to about 1.8 w / v%, about 1.8 w / v% to about 1.9 w / v%, about 1.9 w / v% to about 2.0 w / v%, about 0.75 w / v% to about 1.25 w / v%, about 0.75 w / v%, about 0.8 w / v%, about 0.85 w / v%, about 0.9 w / v%, about 0.95 w / v%, or about 1.0 w / v% of an antioxidant or a combination of antioxidants.

[0097]

[0106] According to some embodiments, the antioxidant is selected from the group consisting of ascorbic acid or its salt, cysteine, such as N-acetylcysteine, bisulfite or its salt, glutathione, tyrosinase inhibitor, divalent cation, butylated hydroxytoluene (BHT), beta hydroxy acid (BHA) tocopherol, gentisic acid, tocopherol, tocopherol derivatives, thioglycerol, and any combination thereof. According to some embodiments, the antioxidant is ascorbic acid. According to some embodiments, the antioxidant is N-acetylcysteine ​​(NAC). According to some embodiments, the first pharmaceutical composition comprises a combination of ascorbic acid and NAC. For example, provided herein is a first pharmaceutical composition suitable for, e.g., subcutaneous administration, comprising about 0.01% to about 1% by weight of an ingredient selected from the group consisting of about 0.1% to about 10% by weight of ascorbic acid or a pharmaceutically acceptable salt thereof, NAC, L-cysteine, and a pharmacologically acceptable salt thereof, about 2% to about 16% by weight of levodopa or an ester thereof, and about 0.6% to about 2% by weight of carbidopa or an ester thereof.

[0098]

[0107] According to some embodiments, the first pharmaceutical composition comprises a base. According to some embodiments, the base is selected from the group consisting of arginine, NaOH, tris(hydroxymethyl)aminomethane (TRIS), NH4OH, ethylenediamine, diethylamine, ethanolamine, diethanolamine, meglumine, and any combination thereof. According to some embodiments, the base is arginine.

[0099]

[0108] According to some embodiments, the first pharmaceutical composition comprises about 5 w / v% to about 30 w / v% of the base. According to some embodiments, the first pharmaceutical composition comprises about 5 w / v% to about 10 w / v%, about 10 w / v% to about 15 w / v%, about 15 w / v% to about 20 w / v%, about 20 w / v% to about 25 w / v%, about 25 w / v% to about 30 w / v%, about 12.5 w / v% to 17.5 w / v%, or about 15 w / v% or about 15.2 w / v% of the base.

[0100]

[0109] According to some embodiments, the first pharmaceutical composition comprises a surfactant. According to some embodiments, the surfactant is selected from Tween-80, Tween-60, Tween-40, Tween-20, Tween-65, Tween-85, Span 20, Span 40, Span 60, Span 80, Span 85, polyoxyl 35 castor oil (Cremophor EL), polyoxyethylene-660 hydroxystearate (macrogol 660), or Poloxamer 188 (Pluronic® F-68), or any combination thereof. The first pharmaceutical composition of the present invention may comprise about 0.1 to about 3.0 w / v% of a surfactant or a combination of two or more surfactants. According to some embodiments, the first pharmaceutical composition comprises about 0.1 to about 0.2 w / v%, about 0.2 to about 0.3 w / v%, about 0.3 to about 0.4 w / v%, about 0.4 to about 0.5 w / v%, about 0.5 to about 0.6 w / v%, about 0.6 to about 0.7 w / v%, about 0.7 to about 0.8 w / v%, about 0.8 to about 0.9 w / v%, about 0.9 to about 1.0 w / v%, about 1.0 to about 1.5 w / v%, about 1.5 to about 2.0 w / v%, about 2.0 to about 2.5 w / v%, about 2.5 to about 3.0 w / v% of a surfactant or a combination of two or more surfactants.

[0101]

[0110] The first pharmaceutical composition may further comprise additional pharmaceutically acceptable excipients, such as N-methylpyrrolidone (NMP), polyvinylpyrrolidone (PVP), propylene glycol, preservatives, pharmaceutically acceptable vehicles, stabilizers, dispersing agents, suspending agents, amino sugars, calcium chelators, protease inhibitors, or any combination thereof. The first pharmaceutical composition of the present invention may comprise about 5.0 to about 80.0 wt.% of additional pharmaceutically acceptable excipients, such as solvents, such as NMP or buffers, or any other cosolvents. For example, provided herein is a pharmaceutically acceptable first composition comprising about 6 wt.% levodopa, about 0.75 wt.% carbidopa, about 10 wt.% to about 20 wt.% arginine, about 0.5 wt.% L-cysteine ​​or NAC, and / or about 0.5 wt.% ascorbic acid or a salt thereof. An exemplary first pharmaceutical composition (e.g., Formulation A) may comprise about 6% by weight levodopa, about 0.75% by weight carbidopa, and about 14% to about 16% by weight arginine. Another exemplary pharmaceutical composition may comprise about 6% by weight levodopa, about 0.75% by weight carbidopa, about 14% to about 16% by weight arginine, about 0.5% by weight ascorbic acid, and about 0.5% NAC.

[0102]

[0111] According to some embodiments, the first pharmaceutical composition of the present invention comprises about 5.0 to about 10.0 w / v%, about 10.0 to about 15.0 w / v%, about 15.0 to about 20.0 w / v%, about 20.0 to about 25.0 w / v%, about 25.0 to about 30.0 w / v%, about 30.0 to about 35.0 w / v%, about 35.0 to about 40.0 w / v%, about 40.0 to about 45.0 w / v%. / v%, about 45.0 to about 50.0 w / v%, about 50.0 to about 55.0 w / v%, about 55.0 to about 60.0 w / v%, about 60.0 to about 65.0 w / v%, about 65.0 to about 70.0 w / v%, about 70.0 to about 75.0 w / v%, or about 75.0 to about 80.0 w / v% of a solvent, such as NMP, a buffer, or any other co-solvent.

[0103]

[0112] According to some embodiments, the first pharmaceutical composition further comprises a buffer. According to some embodiments, the buffer is selected from citrate buffer, citric acid buffer, sodium acetate buffer, acetic acid buffer, tartrate buffer, phosphate buffer, succinate buffer, Tris buffer, glycine buffer, hydrochloric acid buffer, potassium hydrogen phthalate buffer, sodium buffer, sodium citrate tartrate buffer, sodium hydroxide buffer, sodium dihydrogen phosphate buffer, disodium hydrogen phosphate buffer, tromethamine (TRIS), or any combination thereof. The first pharmaceutical composition may comprise about 0.1 to about 30.0 w / v % of the buffer. According to some embodiments, the first pharmaceutical composition comprises about 0.1 to about 1.0 w / v%, about 1.0 to about 2.0 w / v%, about 2.0 to about 3.0 w / v%, about 3.0 to about 4.0 w / v%, about 4.0 to about 5.0 w / v%, about 5.0 to about 6.0 w / v%, about 6.0 to about 7.0 w / v%, about 8.0 to about 9.0 w / v%, about 9.0 to about 10.0 w / v%, about 10.0 to about 15.0 w / v%, about 15.0 to about 20.0 w / v%, about 20.0 to about 25.0 w / v%, or about 25.0 to about 30.0 w / v% of the buffer.

[0104]

[0113] According to some embodiments, the first pharmaceutical composition further comprises an acid or base, for example, to provide a predefined pH to the composition. According to some embodiments, the acid is selected from HCl, HBr, methanesulfonic acid, ascorbic acid, acetic acid, citric acid, or any combination thereof. According to some embodiments, the base is selected from NaOH, Ca(OH), ammonium hydroxide, arginine, magnesium hydroxide, potassium hydroxide, meglumine, tromethamine (TRIS), triethylamine, diisopropylethylamine, diazabicycloundecane, or any combination thereof. The first pharmaceutical composition may comprise about 0.1 to about 30.0 w / v % of a base or acid. According to some embodiments, the first pharmaceutical composition comprises about 0.1 to about 1.0 w / v%, about 1.0 to about 2.0 w / v%, about 2.0 to about 3.0 w / v%, about 3.0 to about 4.0 w / v%, about 4.0 to about 5.0 w / v%, about 5.0 to about 6.0 w / v%, about 6.0 to about 7.0 w / v%, about 8.0 to about 9.0 w / v%, about 9.0 to about 10.0 w / v%, about 10.0 to about 11.0 w / v%, about 11.0 to about 12.0 w / v%, about 12.0 to about 13.0 w / v%, about 13.0 to about 14.0 w / v%, about 14.0 to about 15.0 w / v%, or about 15.0 to about 16. 0 w / v%, about 16.0 to about 17.0 w / v%, about 17.0 to about 18.0 w / v%, about 18.0 to about 19.0 w / v%, about 19.0 to about 20.0 w / v%, about 20.0 to about 21.0 w / v%, about 21.0 to about 22.0 w / v%, about 22.0 to about 23.0 w / v%, about 23.0 to about 24.0 w / v%, about 24.0 to about 25.0 w / v%, about 25.0 to about 26.0 w / v%, about 26.0 to about 27.0 w / v%, about 27.0 to about 28.0 w / v%, about 28.0 to about 29.0 w / v%, or about 29.0 to about 30.0 w / v% of a base or acid.

[0105]

[0114] The pH of the first pharmaceutical composition of the present invention may be about 4.5 to about 10 at about 25°C. According to some embodiments, the pH of the first pharmaceutical composition is about 4.5 to about 5 at about 25°C. According to some embodiments, the pH of the first pharmaceutical composition is about 5 to about 6 at about 25°C. According to some embodiments, the pH of the first pharmaceutical composition is about 6 to about 7 at about 25°C. According to some embodiments, the pH of the first pharmaceutical composition is about 7 to about 8 at about 25°C. According to some embodiments, the pH of the first pharmaceutical composition is about 8 to about 9 at about 25°C. According to some embodiments, the pH of the first pharmaceutical composition is about 9 to about 10 at about 25°C. According to some embodiments, the pH of the first pharmaceutical composition is about 4.5 to about 5.5 at about 25°C. According to some embodiments, the pH of the first pharmaceutical composition is about 5.5 to about 6.5 at about 25°C. According to some embodiments, the pH of the first pharmaceutical composition is about 6.5 to about 7.5 at about 25°C. According to some embodiments, the pH of the first pharmaceutical composition is about 7.5 to about 8.5 at about 25°C. According to some embodiments, the pH of the first pharmaceutical composition is about 8.5 to about 9.5 at about 25°C. According to some embodiments, the pH of the first pharmaceutical composition is about 9.5 to about 10 at about 25°C. According to some embodiments, the pH of the first pharmaceutical composition is about 9.5 at about 25°C. According to some embodiments, an acid or base is added to the first pharmaceutical composition to provide the composition with a predefined pH value. According to some embodiments, the acid is selected from HCl, HBr, methanesulfonic acid, ascorbic acid, acetic acid, citric acid, or any combination thereof. According to some embodiments, the base is selected from NaOH, arginine, an amine base, any base previously mentioned herein, and any combination thereof.

[0106]

[0115] According to some embodiments, the second pharmaceutical composition is administered when desired and / or required, for example, when symptoms from the neurological or movement disorder require such administration, or according to a predefined treatment protocol. The assessment of when to administer the second pharmaceutical composition can be performed by a caregiver, a physician, the patient to whom the composition is being administered, or any combination thereof, resulting from consultation and / or shared decision-making, etc. According to some embodiments, a system assisted by any type of sensor can provide data for determining the need to administer the second pharmaceutical composition. The data can be delivered to a caregiver, a physician, a patient, or any combination thereof, via any means, for example, an electronic device, such as a smartphone, a dedicated console, a tablet, email, a dedicated or known application, etc.

[0107]

[0116] According to some embodiments, the second pharmaceutical composition is administered at predefined times, predefined intervals, or both, set, for example, according to a treatment protocol or according to data received from the patient, caregiver, physician, sensor, etc. The predetermined times and / or intervals may be reset at any time, for example, in consideration of data received from the patient, caregiver, sensor, physician's evaluation, etc.

[0108]

[0117] According to some embodiments, the second pharmaceutical composition is orally administered substantially simultaneously with the start of the infusion time course. According to some embodiments, the second pharmaceutical composition is orally administered about 1, 2, 3, 4, or 5 hours after the start of the infusion time course. Note that the "start of the infusion time course" may be a time of day (e.g., when a new vial is introduced into the system, the cartridge is replaced, the infusion set is replaced, etc.).

[0109]

[0118] According to some embodiments, the orally administered second pharmaceutical composition is a morning oral dose. According to some embodiments, the morning oral dose comprises levodopa, a levodopa salt, a levodopa prodrug, or any combination thereof. According to some embodiments, the morning oral dose comprises one of: 25 mg levodopa, 50 mg levodopa, 75 mg levodopa, 95 mg levodopa, 100 mg levodopa, 125 mg levodopa, 145 mg levodopa, 150 mg levodopa, 195 mg levodopa, 200 mg levodopa, 245 mg levodopa, or 250 mg levodopa.

[0110]

[0119] According to some embodiments, the morning oral dose comprises (a) levodopa, a levodopa salt, or a levodopa prodrug, (b) a dopa decarboxylase inhibitor (DDCI), a DDCI salt, or a DDCI prodrug, or (c) any combination thereof.

[0111]

[0120] According to some embodiments, the second pharmaceutical composition is administered up to 20 times per day. According to some embodiments, the second pharmaceutical composition is administered about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 times per day. According to some embodiments, the second pharmaceutical composition is administered about 3 to 7 times per day. According to some embodiments, the second pharmaceutical composition is administered about 4 to 6 times per day. According to some embodiments, the second pharmaceutical composition is administered at a frequency of about 30 minutes to about 24 hours. According to some embodiments, the second pharmaceutical composition is administered at a frequency of about 30 minutes to about 1 hour, about 1 hour to 2 hours, about 2 hours to 3 hours, about 3 hours to about 4 hours, about 4 hours to about 5 hours, about 5 hours to about 6 hours, about 6 hours to 7 hours, about 7 hours to about 8 hours, about 8 hours to about 9 hours, about 9 hours to about 10 hours, about 11 hours to about 12 hours, about 10 hours to about 11 hours, about 13 hours to about 14 hours, about 12 hours to about 13 hours, about 15 hours to about 16 hours, about 14 hours to about 15 hours, about 17 hours to about 18 hours, about 16 hours to about 17 hours, about 19 hours to about 20 hours, about 18 hours to about 19 hours, about 21 hours to about 22 hours, about 20 hours to about 21 hours, about 23 hours to about 24 hours, or about 22 hours to about 23 hours.

[0112]

[0121] The interval between one administration and the next may likewise vary depending, for example, on patient / caregiver / physician observation and assessment, on data received from any suitable sensor, on predefined treatment protocols, on any combination thereof, etc.

[0113]

[0122] According to some embodiments, the administered dose of the levodopa component in the second pharmaceutical composition is the same for each administration. According to some embodiments, the administered dose of the levodopa component in the second pharmaceutical composition may vary between different administrations. According to some embodiments, the administered dose of the levodopa component in the second pharmaceutical composition is about 10 mg / day to about 3000 mg / day, about 10 mg / day to about 50 mg / day, about 50 mg / day to about 100 mg / day, about 100 mg / day to about 150 mg / day, about 150 mg / day to about 250 mg / day, about 250 mg / day to about 350 mg / day, about 350 mg / day to about 500 mg / day, about 500 mg / day to about 750 mg / day, about 750 mg / day to about 800 mg / day, about 800 mg / day to about 900 mg / day, about 900 mg / day to about 1000 mg / day, about 100 mg / day to about 150 mg / day, about 150 mg / day to about 250 mg / day, about 250 mg / day to about 350 mg / day, about 350 mg / day to about 500 mg / day, about 500 mg / day to about 750 mg / day, about 1000 mg / day to about 150 ...0 mg / day to about 250 mg / day, about 250 mg / day to about 350 mg / day, about g / day to about 1000 mg / day, about 1000 mg / day to about 1250 mg / day, about 1250 mg / day to about 1500 mg / day, about 1500 mg / day to about 1750 mg / day, about 1750 mg / day to about 2000 mg / day, about 2000 mg / day to about 2250 mg / day, about 2250 mg / day to about 2500 mg / day, about 2500 mg / day to about 2750 mg / day, or about 2750 mg / day to about 3000 mg / day. According to some embodiments, the dose of the levodopa component in the second pharmaceutical composition is about 100 mg / day to about 1800 mg / day. According to some embodiments, the dose of the levodopa component in the second pharmaceutical composition is about 350 mg / day to about 700 mg / day.

[0114]

[0123] It should be noted that the dosage is determined according to the time the composition is administered to the patient, so if several tablets, e.g., four tablets, each containing 100 mg of levodopa, are administered to the patient substantially simultaneously, the dosage of levodopa in the second pharmaceutical composition would be considered to be 400 mg in such an example. Furthermore, the daily dose may consist of several dosages that are not necessarily identical to each other; for example, the patient may be administered 100 mg at 8:00 AM, 200 mg at 10:00 AM, 100 mg at 3:00 PM, and 75 mg at 7:00 PM, so that the dosage of the levodopa component in the second pharmaceutical composition would be considered to be 475 mg / day.

[0115]

[0124] According to some embodiments, the dose of the levodopa component in the second pharmaceutical composition is about 10 mg to about 500 mg per administration, about 10 mg to about 25 mg per administration, about 25 mg to about 50 mg per administration, about 50 mg to about 75 mg per administration, about 75 mg to about 100 mg per administration, about 100 mg to about 150 mg per administration, about 150 mg to about 200 mg per administration, about 200 mg to about 250 mg per administration, about 250 mg to about 300 mg per administration, about 300 mg to about 350 mg per administration, about 350 mg to about 400 mg per administration, about 400 mg to about 450 mg per administration, or about 450 mg to about 500 mg per administration. According to some embodiments, the dose varies between different administrations. According to other embodiments, the dose remains constant for at least two administrations, eg, for 24 hours, 3 days, 1 week, etc.

[0116]

[0125] In certain embodiments, the dose of the levodopa component in the second pharmaceutical composition is about 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 200 mg, or 250 mg of levodopa, e.g., in an immediate-release tablet or capsule. According to some embodiments, the amount of the levodopa component in the second pharmaceutical composition is about 95 mg, about 145 mg, about 195 mg, or about 245 mg of levodopa, e.g., in an extended-release form, e.g., a tablet or capsule.

[0117]

[0126] As noted above, the levodopa component can be levodopa, a levodopa salt, a levodopa prodrug, or any combination thereof. According to some embodiments, the levodopa component is levodopa.

[0118]

[0127] According to some embodiments, the dose of the carbidopa component in the second pharmaceutical composition is from about 2.5 mg to about 50 mg per dose, from about 2.5 mg to about 20 mg per dose, from about 2.5 mg to about 25 mg per dose, from about 2.5 mg to about 35 mg per dose, from about 2.5 mg to about 40 mg per dose, from about 15 mg to about 20 mg per dose, from about 15 mg to about 25 mg per dose, from about 15 mg to about 35 mg per dose, from about 15 mg to about 4 ...5 mg per dose, from about 15 mg to about 35 mg per dose, from about 15 mg to about 40 mg per dose, from about 15 mg to about 25 mg per dose, from about 15 mg to about 35 mg per dose, from about 15 mg to about 40 mg per dose, from about 15 mg to about 25 mg per dose, from about 15 mg to about 35 mg per dose, from about 15 mg to about 40 mg per dose, from about 15 mg to about 25 mg per dose, from about 15 mg to about 25 mg per dose, from about 15 mg to about 35 mg per dose, from about 15 mg to about 40 mg per dose, from about 15 mg About 15 mg to about 50 mg per dose, about 20 mg to about 25 mg per dose, about 20 mg to about 35 mg per dose, about 20 mg to about 40 mg per dose, about 20 mg to about 50 mg per dose, about 25 mg to about 35 mg per dose, about 25 mg to about 40 mg per dose, about 25 mg to about 50 mg per dose, about 35 mg to about 40 mg per dose, about 35 mg to about 50 mg per dose, about 40 mg to about 50 mg per dose. According to some embodiments, the dose of the carbidopa component in the second pharmaceutical composition comprises 2.5 mg, 18.57 mg, 25 mg, 31.25 mg, 37.5 mg, or 50 mg of carbidopa.

[0119]

[0128] The second pharmaceutical composition can be in any suitable oral form, such as pills, hard or soft capsules, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, syrups, or elixirs. The second pharmaceutical composition can be in an immediate-release form or any type of controlled-release form, such as sustained-release, extended-release, delayed-release, or extended-release. As described above, the second pharmaceutical composition can contain at least two active ingredients, such as levodopa and carbidopa. Note that each active ingredient in the second pharmaceutical composition can be formulated in a different release form, for example, levodopa can be in a controlled-release form while carbidopa is in an immediate-release form, or vice versa.

[0120]

[0129] According to some embodiments, the second pharmaceutical formulation is administered only during high activity / wake times, e.g., daytime, such that the administration interval is narrower during high activity / wake times than during other parts of the day, e.g., low activity / evening times. According to further embodiments, the dose of the second pharmaceutical formulation provided during high activity / wake times is higher than the dose administered during other parts of the day, e.g., low activity / evening times. According to some embodiments, a 24-hour administration regimen may be devised and remain constant for a certain number of days, while within the same day, the regimen may vary based on wakefulness, activity, etc. According to some embodiments, the administration regimen may vary from day to day and within the same day.

[0121]

[0130] Embodiments of the present invention further relate to a method of treating a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, the method comprising: levodopa, a levodopa salt, a levodopa prodrug, or any combination thereof; and dopa decarboxylase inhibitors (DDCI), DDCI salts, DDCI prodrugs, or any combination thereof parenterally administering a first pharmaceutical composition comprising: Accompanying this, Levodopa, levodopa salts, levodopa prodrugs; dopa decarboxylase inhibitors (DDCI), DDCI salts, DDCI prodrugs; or any combination thereof orally administering a morning oral dose composition comprising: Includes.

[0122]

[0131] A further embodiment of the invention is a combination of: levodopa, a levodopa salt, a levodopa prodrug, or any combination thereof; and dopa decarboxylase inhibitors (DDCI), DDCI salts, DDCI prodrugs, or any combination thereof a first pharmaceutical composition comprising: Levodopa, levodopa salts, levodopa prodrugs; dopa decarboxylase inhibitors (DDCI), DDCI salts, DDCI prodrugs; or any combination thereof A second pharmaceutical composition comprising wherein the first pharmaceutical composition is formulated as a parenteral composition and the second pharmaceutical composition is formulated as an oral composition.

[0123]

[0132] A further embodiment of the present invention comprises: levodopa, a levodopa salt, a levodopa prodrug, or any combination thereof; and dopa decarboxylase inhibitors (DDCI), DDCI salts, DDCI prodrugs, or any combination thereof a first pharmaceutical composition in parenteral form comprising Levodopa, levodopa salts, levodopa prodrugs; dopa decarboxylase inhibitors (DDCI), DDCI salts, DDCI prodrugs; or any combination thereof a second pharmaceutical composition in oral form comprising: Instructions for the concomitant administration of a first pharmaceutical composition and a second pharmaceutical composition for the treatment of a neurological or movement disorder, such as Parkinson's disease The present invention relates to a kit comprising:

[0124]

[0133] A further embodiment of the present invention comprises: levodopa, a levodopa salt, a levodopa prodrug, or any combination thereof; and dopa decarboxylase inhibitors (DDCI), DDCI salts, DDCI prodrugs, or any combination thereof a first pharmaceutical composition in parenteral form comprising: Instructions for the concomitant administration of a first pharmaceutical composition and a second pharmaceutical composition for the treatment of a neurological or movement disorder, such as Parkinson's disease and the second pharmaceutical composition is provided separately.

[0125]

[0134] A further embodiment of the present invention is a method of treating Parkinson's disease in a patient in need thereof, wherein the patient has previously been administered a previous form of levodopa other than a 1:4 ratio immediate release carbidopa-levodopa tablet; switching the patient from their previous form of levodopa to oral immediate-release levodopa-carbidopa 100 / 25 mg tablets; subcutaneously administering to the patient a first pharmaceutically acceptable liquid composition comprising levodopa over a subcutaneous infusion time course of at least about 24 hours or more; orally administering to the patient at least one oral dosage form comprising levodopa before or during the subcutaneous infusion time course; The present invention relates to a method comprising:

[0126]

[0135] A further embodiment of the present invention is a method of treating Parkinson's disease in a patient in need thereof, wherein the patient has previously been administered a previous form of levodopa; switching the patient from a previous form of levodopa to an oral immediate-release levodopa-carbidopa form; after said switching, subcutaneously administering to the patient a first pharmaceutically acceptable liquid composition comprising levodopa over a subcutaneous infusion time course of at least about 24 hours or more; orally administering to the patient at least one oral dosage form comprising levodopa before or during the subcutaneous infusion time course; The present invention relates to a method comprising:

[0127]

[0136] A further embodiment of the present invention is a method of treating Parkinson's disease in a patient in need thereof, wherein the patient has previously been administered a previous form of levodopa, the method comprising: administering to the patient an amount of oral immediate-release levodopa by switching the patient from a previous form of levodopa to an oral immediate-release levodopa form; after said switching, subcutaneously administering to the patient a subcutaneous amount of a first pharmaceutically acceptable liquid composition comprising levodopa over a subcutaneous infusion time course of at least about 24 hours or more; Including, If the amount of the oral immediate-release form of levodopa is greater than the subcutaneous amount of levodopa, the amount of the oral immediate-release form of levodopa is reduced by approximately the amount of the subcutaneous amount of levodopa, and the patient is administered the remaining amount of oral immediate-release levodopa; If the amount of oral immediate-release levodopa is less than the subcutaneous amount of levodopa, the patient is not administered oral immediate-release levodopa except for the morning dose of oral immediate-release levodopa administered before or during the subcutaneous infusion time course. Regarding the method.

[0128]

[0137] A further embodiment of the present invention is a method of treating Parkinson's disease in a patient in need thereof, wherein the patient has previously been administered a previous form of levodopa, the method comprising: administering to the patient an initial daily dose of oral immediate-release levodopa by switching the patient from a previous form of levodopa to an oral immediate-release levodopa form; after said switching, subcutaneously administering to the patient a first pharmaceutically acceptable liquid composition over a subcutaneous infusion time course of at least about 24 hours or more in an amount that delivers about 720 mg of levodopa to the patient over at least about 24 hours; Including, If the initial daily dose of oral immediate-release levodopa is greater than about 700 mg, the amount of oral immediate-release levodopa is reduced by about 700 mg and the patient is administered a remaining amount of oral immediate-release levodopa equal to the initial daily dose of oral immediate-release levodopa minus 700 mg; If the initial daily amount of oral immediate-release levodopa is less than about 700 mg, the patient is administered only the morning dose of oral immediate-release levodopa administered before or during the subcutaneous infusion time course. Regarding the method.

[0129]

[0138] In certain embodiments of the methods described herein, the concomitant administration of a first composition (parenterally, e.g., subcutaneously) and a second composition (e.g., an oral tablet) to a patient results in a higher area under the curve (AUC) for levodopa from time 0 to the end of parenteral infusion, e.g., subcutaneous infusion, compared to the combined AUC for levodopa in the patient when the first composition and the second composition are not administered concomitantly, and the total amount of levodopa administered is the same whether administered concomitantly or non-concomitantly.

[0130]

[0139] Unless explicitly stated, the method embodiments described herein are not bound to a particular order or sequence. In addition, some of the described method embodiments or elements thereof may occur or be performed simultaneously, contemporaneously, or concurrently.

[0131]

[0140] It will also be recognized that certain features of the invention may be provided in combination in a single embodiment. Conversely, various elements of the invention that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination, or as appropriate, with any other described embodiment of the invention. Moreover, certain features described in the context of various embodiments should not be construed as essential features of that embodiment, unless the embodiment is invalid without those elements.

[0132]

[0141] The various embodiments and aspects of the present invention, as precisely outlined above and claimed in the claims section below, can be supported by; but should not be limited by, the following examples.

[0133] Example [Example]

[0134]

[0142] A study was performed to evaluate the plasma exposure of levodopa (LD) and carbidopa (CD) after coadministration by both subcutaneous (SC) and oral administration. Therefore, results from combined SC+oral administration were compared with those from SC administration alone and from oral administration alone. Additive plasma exposure and PK profiles were expected; that is, SC+oral coadministration was expected to provide results equivalent to the additive results of SC and oral administration when each was administered separately.

[0135] method

[0143] Sixteen healthy subjects (aged 18-50 years) were treated in a crossover fashion, i.e., sequentially. A washout period of 6 days was observed between the two subsequent treatments:

[0144] Treatment A: A total dose of 180 / 22.5 mg LD / CD (Formulation A) was administered by SC infusion over 8 hours at a steady infusion rate.

[0136]

[0145] Treatment B: 100 / 25 mg immediate release (IR) tablets of LD / CD were administered orally at time 0 h.

[0146] After a 32-hour washout period, the same 16 healthy subjects were administered LC / CD orally and subcutaneously according to the following procedure:

[0147] Treatment C: Four hours after the start of the infusion, a dose of 153.6 / 19.2 LD / CD (Formulation A) was administered by SC infusion over 8 hours at a steady infusion rate, in combination with a single co-administration of oral IR LD / CD 100 / 25 mg tablets. Total LD / CD dose: 253.6 / 44.2 mg.

[0137]

[0148] Blood samples were collected at the following time points:

[0149] Treatment A: 0 (before the start of treatment), 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 5.5 h, 6 h, 7 h, 8 h (before the end of the infusion).

[0138]

[0150] Treatment B: 0 (before the start of treatment), 0.5h, 1h, 2h, 3h, 4h.

[0151] Treatment C: 0 (before the start of treatment), 0.5 h, 1 h, 2 h, 3 h, 4 h, 4.5 h, 5 h, 5.5 h, 6 h, 7 h, 8 h (before the end of the infusion).

[0139] result

[0152] Normalized AUC of LD and CD for Treatment C from combined SC and oral treatments as described above 0~8 was calculated to obtain the AUC from Treatment A (8 h SC injection) 0~8 ) and Treatment B (AUC from one IR oral tablet 0~4 ) and compared with the sum of the normalized LD and CD AUCs obtained from the LD and CD AUCs. The results are shown in Tables 1 and 2 below.

[0140] [Table 1]

[0141] [Table 2]

[0142]

[0153] The combined / additive results of Treatments A and B (combined, i.e., added to each other) were expected to be substantially the same as the results obtained from Treatment C, which essentially combines Treatments A and B within that treatment regime.

[0143]

[0154] Surprisingly, as shown in the results above, the treatment C normalized AUC was significantly lower than the sum of the normalized AUCs for treatments A and B mentioned above. 0~8 Comparison of the LD and CD AUCs demonstrated a higher than expected LD AUC, whereas in contrast, the CD AUC for Treatment C was lower than expected.

[0144]

[0155] Specifically, as shown in Table 1, the ratio of the LD-normalized AUC from treatment C compared to that obtained in treatment A+B (both added together to simulate SC+oral administration in treatment C) for each individual was greater than 1.0, with a mean ratio of 1.245 and a range of 1.057-1.402. Furthermore, as shown in Table 2, for most individuals, the ratio of the CD-normalized AUC from treatment C compared to that obtained in treatment A+B was less than 1.0, with a mean ratio of 0.869 and a range of 0.773-1.080.

[0145]

[0156] Thus, surprisingly, the combined SC+oral treatment achieves higher LD levels than would be expected from the addition of the two doses when each is given separately. In contrast, the CD levels obtained from the combined SC+oral treatment are lower than would be expected from the addition of the two doses when each is given separately. The lower CD results obtained with the combined treatment make the higher-than-expected LD levels even more surprising (the amount of CD is reduced, but the amount of LD is actually increased; this is the opposite of what would be expected, since CD generally inhibits the peripheral metabolism of LD, so the lower the amount of CD, the lower the expected amount of LD).

[0146] equivalent

[0157] While specific embodiments of the subject invention have been discussed, the foregoing specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification and such variations.

[0147]

[0158] Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and the like used in the specification and claims are to be understood as being modified in all instances by the term "about." Furthermore, when a particular value is recited in the specification and claims, unless otherwise indicated, the term "about" means that an acceptable error range, e.g., up to 5% or 10% for the particular value, should be assumed.

[0148] Incorporation by Reference

[0159] The entire contents of all patents, published patent applications, websites, and other references cited herein are expressly incorporated herein by reference in their entirety.

Claims

1. (a) levodopa, a levodopa salt, a levodopa prodrug, or any combination thereof; and dopa decarboxylase inhibitors (DDCI), DDCI salts, DDCI prodrugs, or any combination thereof a first pharmaceutical composition in parenteral form comprising (b) levodopa, a levodopa salt, a levodopa prodrug; a dopa decarboxylase inhibitor (DDCI), a DDCI salt, a DDCI prodrug; or any combination thereof. a second pharmaceutical composition in oral form comprising (c) instructions for the concomitant administration of the first pharmaceutical composition and the second pharmaceutical composition for the treatment of a neurological or movement disorder. Kit including:

2. (a) levodopa; and Carbidopa a first pharmaceutical composition in parenteral form comprising (b) levodopa a second pharmaceutical composition in oral form comprising (c) instructions for the concomitant administration of the first pharmaceutical composition and the second pharmaceutical composition for the treatment of Parkinson's disease. Kit including:

3. The kit of claim 2, wherein the first pharmaceutical composition in parenteral form further contains arginine.

4. The kit of claim 2, wherein the first pharmaceutical composition in parenteral form further contains at least one antioxidant.

5. The kit of claim 2, wherein the second pharmaceutical composition in oral form further contains carbidopa.

6. A pharmaceutical combination for the treatment of Parkinson's disease comprising: (a) a subcutaneous liquid composition comprising levodopa and carbidopa in an amount suitable to subcutaneously deliver about 720 mg of levodopa and about 90 mg of carbidopa to a patient over a time course of at least about 24 hours; (b) one or more immediate release tablets or capsules containing 100 mg of levodopa suitable for oral delivery of levodopa prior to or during delivery of the subcutaneous liquid composition; A medicine comprising a combination of the above.

7. The combination pharmaceutical of claim 6, wherein the subcutaneous liquid composition further comprises arginine.

8. The combination pharmaceutical of claim 6, wherein the subcutaneous liquid composition further comprises at least one antioxidant.

9. The pharmaceutical combination of claim 6, wherein one or more immediate release tablets or capsules further contain carbidopa.

10. The pharmaceutical combination of claim 6, wherein delivery of the subcutaneous liquid composition and delivery of one or more immediate release tablets or capsules results in a higher plasma levodopa area under the curve (AUC) from time 0 to the end of the patient's infusion period compared to the combination of: i) the plasma levodopa AUC from time 0 to the end of the infusion period when the patient is administered a pharma- ceutical acceptable liquid composition alone subcutaneously for at least about 24 hours; and ii) the plasma levodopa AUC in a patient administered oral levodopa alone.

11. A pharmaceutical combination for the treatment of Parkinson's disease comprising: (a) a subcutaneous liquid composition comprising levodopa, carbidopa, arginine, and an antioxidant in an amount suitable to subcutaneously deliver about 720 mg of levodopa and about 90 mg of carbidopa to a patient for at least about 24 hours; (b) at least one oral dosage form comprising levodopa, suitable for oral delivery of levodopa prior to or during delivery of the subcutaneous liquid composition; A medicine comprising a combination of the above.

12. 12. The pharmaceutical combination of claim 11, wherein the oral dosage form comprises one of: 50 mg levodopa, 75 mg levodopa, 95 mg levodopa, 100 mg levodopa, 125 mg levodopa, 145 mg levodopa, 150 mg levodopa, 195 mg levodopa, 200 mg levodopa, 245 mg levodopa, or 250 mg levodopa.

13. The pharmaceutical combination of claim 11, wherein the oral dosage form is a morning oral dose.

14. The combination pharmaceutical of claim 11, wherein the patient exhibits motor fluctuations.

15. A pharmaceutical combination for the treatment of Parkinson's disease comprising: (a) a subcutaneous liquid composition comprising levodopa, carbidopa, arginine, and an antioxidant in an amount suitable to subcutaneously deliver about 720 mg of levodopa and about 90 mg of carbidopa to a patient for at least about 24 hours; (b) at least one tablet or capsule containing 100 mg of levodopa and 25 mg of carbidopa suitable for daily oral delivery of levodopa and carbidopa prior to or during delivery of the subcutaneous liquid composition; A medicine comprising a combination of the above.

16. A pharmaceutical combination for the treatment of Parkinson's disease comprising: (a) a subcutaneous liquid composition comprising levodopa, carbidopa, arginine, and an antioxidant in an amount suitable to subcutaneously deliver about 370 mg to about 720 mg of levodopa and about 46 mg to about 90 mg of carbidopa to a patient over a period of at least about 24 hours; (b) at least one oral dosage form comprising levodopa, suitable for oral delivery of levodopa prior to or during delivery of the subcutaneous liquid composition; A medicine comprising a combination of the above.

17. The combination pharmaceutical of claim 16, wherein the oral dosage form comprises one of: 50 mg levodopa, 75 mg levodopa, 95 mg levodopa, 100 mg levodopa, 125 mg levodopa, 145 mg levodopa, 150 mg levodopa, 195 mg levodopa, 200 mg levodopa, 245 mg levodopa, or 250 mg levodopa.

18. The pharmaceutical combination of claim 16, wherein the oral dosage form is a morning oral dose.

19. The combination pharmaceutical of claim 16, wherein the patient exhibits motor fluctuations.

20. The pharmaceutical combination of claim 16, wherein delivery of the subcutaneous liquid composition and delivery of one or more immediate release tablets or capsules results in a higher plasma levodopa area under the curve (AUC) from time 0 to the end of the patient's infusion period compared to the combination of: i) the plasma levodopa AUC from time 0 to the end of the infusion period when the patient is administered a pharma- ceutical acceptable liquid composition alone subcutaneously for at least about 24 hours; and ii) the plasma levodopa AUC in a patient administered oral levodopa alone.